Iovance Biotherapeutics reported second quarter 2026 financial results, announcing record total revenue of $99.3 million and a gross margin of 56%, driven by strong U.S. Amtagvi demand which reached approximately $91 million. The company is reviewing its full-year 2026 revenue guidance of $350 million to $370 million in light of these results, with an update expected in the third quarter. Additionally, the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas based on positive early data from the registrational SARATOGA trial. The company holds approximately $304 million in cash as of June 30, 2026. Iovance Biotherapeutics operates in the biotechnology industry, specializing in developing and commercializing tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors.

Iovance Biotherapeutics, Inc. received marketing authorization from the Therapeutic Goods Administration of Australia for Amtagvi® for the treatment of previously treated advanced melanoma. Additionally, stockholders-at-large at the Annual Meeting of Stockholders held on June 10, 2026, approved an amendment to the Certificate of Incorporation to increase authorized common stock from 500,000,000 to 650,000,000 shares. Iovance Biotherapeutics, Inc. is a biotechnology company that develops and commercializes cell therapies for cancer.